# Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

> **NCT04368728** · PHASE2,PHASE3 · COMPLETED · sponsor: **BioNTech SE** · enrollment: 46969 (actual)

## Conditions studied

- SARS-CoV-2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** BNT162b1
- **BIOLOGICAL:** BNT162b2
- **OTHER:** Placebo
- **BIOLOGICAL:** BNT162b2SA

## Key facts

- **NCT ID:** NCT04368728
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-29
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-02-10
- **Target enrollment:** 46969 (ACTUAL)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04368728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04368728, "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04368728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*